Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.

about

Precision medicine in COPD: where are we and where do we need to go?

P2860

Q58804231-3CBF2243-EE90-4563-A0D7-44B7DDBF3106

P2860

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.

Item

http://www.wikidata.org/entity/Q47718704

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.

@en

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.

@nl

type

Item

label

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.

@en

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.

@nl

prefLabel

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.

@en

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.

@nl

P1476

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.

@en

P2093

Fulvio Braido

http://www.w3.org/2001/XMLSchema#string

Marco Contoli

http://www.w3.org/2001/XMLSchema#string

Nicola Scichilone

http://www.w3.org/2001/XMLSchema#string

Pierachille Santus

http://www.w3.org/2001/XMLSchema#string

P2860

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

Global and regional estimates of COPD prevalence: Systematic review and meta-analysis

A review of national guidelines for management of COPD in Europe

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.

Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease.

Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.

P304

641-647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/15412555.2017.1385056

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29116901

http://www.w3.org/2001/XMLSchema#string

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.

about

P2860

P2860

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698